Beyond the distinction between biomedical and social dimensions of HIV: Prevention through the lens of a social public health

American Journal of Public Health

Volumn 102, Issue 5, 2012, Pages 789-799

  Kippax, Susan ^a   Stephenson, Niamh ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSUMER; ETHICS; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; SEXUAL BEHAVIOR; SOCIOLOGY; SUBSTANCE ABUSE; UNITED NATIONS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; CONSUMER PARTICIPATION; HEALTH EDUCATION; HEALTH POLICY; HEALTH PROMOTION; HIV INFECTIONS; HUMANS; PUBLIC HEALTH; SEXUAL BEHAVIOR; SOCIOLOGY, MEDICAL; SUBSTANCE ABUSE, INTRAVENOUS; UNITED NATIONS;

EID: 84861922417     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300594     Document Type: Article

References (116)

1. Elizabeth Fee and Nancy Krieger, "Understanding AIDS: Historical interpretations and the limits of biomedical individualism," American Journal of Public Health 83, no. 10 (1993): 1477-1486. (Pubitemid 23294982)
2. Joint United Nations Programme on HIV/AIDS, 2006 Report on the Global AIDS Epidemic (Geneva, Switzerland: UNAIDS, 2006).
3. Didier Fassin, When Bodies Remember: Experiences and Politics of AIDS in South Africa, (Berkeley and Los Angeles, Calif: University of California Press, 2007), 189.
4. R.M. Granich et al., "Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for the elimination of HIV transmission: a mathematical model," The Lancet 373, no. 9657 (2009): 48-57.
5. L. Mofenson and J. Mcintyre, "Advances and research directions in the prevention of mother-to-child transmission," The Lancet 355, no. 9222 (2000): 2237-2244. (Pubitemid 30394338)
6. Sevgi O. Aral and Thomas A. Peterman, "Do we know the effectiveness of behavioural interventions?" The Lancet 351, suppl 111 (1998): 33-36. (Pubitemid 128643736)
7. Q. Abdool Karim et al., "Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV in women," Science 329, no. 5996 (2010): 1168-1174.
8. R.C. Bailey et al., "Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial," The Lancet 369, no. 9562 (2007): 643-656. (Pubitemid 46281312)
9. R.M. Grant et al., "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men," New England Journal of Medicine 363, no. 27 (2010): 2587-2599.
10. G.W. Rutherford, "Condoms in concentrated and generalised HIV epidemics," The Lancet 372, no. 9635 (2008): 275-276. (Pubitemid 352020425)
11. C. Bateman, "Male circumcision rollout certain-now for the 'how,'" South African Medical Journal 100, no. 2 (2010): 84-86.
12. G.M. Myers and K.H. Mayer, "Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings," AIDS Patient Care & STDs 25, no. 2 (2011): 63-71;
13. Centers for Disease Control and Prevention, "Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men," MMWR Morbidity and Mortality Weekly Report 60, no. 3 (2011): 65-68.
14. T. Young et al., "Antiretroviral postexposure prophylaxis (PEP) for occupational HIV exposure," Cochrane Database of Systematic Reviews (Jan 24, 2007) (1):CD002835.
15. P. Vernazza, B. Hirschel, and E. Bernasconi, "Les personnes seropositives suivant un TAR efficace ne transmettent pas le VIH par voie sexuelle," Bulletin des Medecins Suisses 89 (2008): 5;
16. M.S. Cohen et al., "Prevention of HIV-1 infection with early antiretroviral therapy," New England Journal of Medicine 365, no. 6 (2011): 493-505.
17. J.S.G. Montaner et al., "Association of highly active antiretroviral therapy coverage, population viral load, and yearly new diagnoses in British Columbia, Canada: a population study," The Lancet 376, no. 9740 (2010): 532-539.
18. M.S. Cohen and S. Fidler, "HIV prevention: where are we now and where are we going?," Current Opinion in HIV and AIDS 5, no. 4 (2010): 265-268.
19. A.E. Grulich and D. Wilson, "Is antiretroviral therapy modifying the HIV epidemic?," The Lancet 376, no. 9755 (2010): 1824;
20. J.D. Shelton et al., "Is antiretroviral therapy modifying the HIV epidemic?," The Lancet 376, no. 9755 (2010): 1824-1825.
21. G.P. Garnett and R. Baggaley, "Treating our way out of the HIV pandemic: could we, would we, should we?," The Lancet 373, no. 9657 (2009): 9-11;
22. P.J. Dodd, G.P. Garnett, and T. Hallett, "Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings," AIDS 24, no. 5 (2010): 729-735.
23. R.M. Granich et al., "Highly active antiretroviral treatment as prevention of HIV transmission: a review of scientific evidence and uptake," Current Opinion in HIV and AIDS 5, no. 4 (2010): 298-304;
24. "The science and practice of HIV prevention," The Lancet 376, no. 9738 (2010): 304.
25. In February 2010, the British Columbia government announced it would invest $48 million over 4 years in a pilot project to enhance outreach to dramatically expand HIV testing and treatment for hard-to-reach, HIV-infected individuals. The pilot project is being led by the British Columbia Centre for Excellence, and evaluated as part of the Centre's innovative Seek and Treat for the Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) research program, http://www.cfenet.ubc.ca/sites/default/files/uploads/news/releases/ China-BCCfE-release-Feb22.pdf (accessed March 17, 2011).
26. China made a landmark announcement at its national HIV/AIDS meeting on February 24, 2011, in proposal calls for widespread HIV testing and treatment for all medically eligible individuals. Over the past year, China has worked collaboratively with the British Columbia Centre for Excellence to help develop its treatment as prevention program, http://www.cfenet.ubc.ca/sites/default/ files/uploads/news/releases/China-BCCfE-release-Feb22.pdf (accessed March 17, 2011).
27. The testing campaign-a public-private partnership-was launched with President Jacob Zuma; it is being tested in 2010 and runs through to June 2011. It will target first-year students at 18 universities across the country and is seeking to test school children. Government departments, together with the South African National AIDS Council, are holding nationwide consultative meetings with members of the education, children's rights, and HIV sectors to formulate a national policy for school-based HIV testing, as well as guidelines and recommendations for the country's nine provinces. South African Health Minister Aaron Motsoaledi said that "Getting tested is only one of nine HIV preventative measures but is arguably one of the most important," http://www.plusnews.org (accessed September 29, 2010).
28. Centers for Disease Control and Prevention, "Interim guidance: preexposure prophylaxis," 65-68.
29. R.F. Baggaley and C. Fraser, "Modelling sexual transmission of HIV: testing the assumptions, validating the predictions," Current Opinion in HIV and AIDS 5, no. 4 (2010): 269-276.
30. AIDS Epidemic Update (Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2009).
31. F. Maggiollo and S. Leone, "Is HAART modifying the HIV epidemic?" The Lancet 376, no. 9740 (2010): 492-493.
32. F. Dabis, M-L. Newell, and B. Hirschel, "HIV drugs for treatment, and for prevention," The Lancet 375, no. 9731 (2010): 2056-2057.
33. See for instance M. Potts et al., "Reassessing HIV prevention," Science, 320, no. 5877 (2008): 749-750;
34. "HIV treatment as prevention-it works," The Lancet 377, no. 9779 (2011): 1719.
35. N. Padian et al., "Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward," The Lancet 372, no. 9638 (2008): 585-599.
36. T.J. Coates, L. Richter, and C. Caceres, "Behavioural strategies to reduce HIV transmission: how to make them work better," The Lancet 372, no. 9639 (2008): 669-684.
37. N.S. Padian et al., "HIV prevention transformed: the new prevention research agenda," The Lancet 378, no. 9787 (2011): 269-278.
38. For example, when in his January 2003 State of the Union address, President George W. Bush announced the US President's Emergency Plan for AIDS Relief (PEPFAR), pledging US $15 billion dollars over 5 years, the US legislation stipulated that 55% of funds were to be spent on treatment, 20% on prevention, 15% on palliative care, and 10% for orphans and vulnerable children (J. Kates and E. Lief, International Assistance for HIV/AIDS in the Developing World: Taking Stock of the G8, Other Donor Governments, and the European Commission, [Washington, DC: Kaiser Family Foundation, 2006]).
39. In a similar way, the WHO "3 by 5 Initiative," launched in 2003, was unashamedly treatment-focused (B. Schwartlander, I. Grub, and J. Perriëns, "The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world," The Lancet 368, no. 9534 [2006]: 541-546). (Pubitemid 44177530)
40. Susan Kippax, "A public health dilemma: a testing question," AIDS Care 18, no. 3 (2006): 230-235;
41. L. Sherr et al., "Voluntary counselling and testing: uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort," AIDS 21, no. 7 (2007): 851-860; (Pubitemid 46573157)
42. Potts et al., "Reassessing HIV prevention," 749-750;
43. S.D. Pinkerton, D.R. Holtgrave, and C.L. Galletly, "Infections prevented by increasing HIV serostatus awareness in the United States, 2001-2004," Journal of Acquired Immune Deficiency Syndromes 47, no. 3 (2008): 354-357; (Pubitemid 351619423)
44. J.A. Denison et al., "HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005," AIDS & Behavior 12, no. 3 (2008): 363-373.
45. In this regard, see S.D. Weiser et al., "Routine testing in Botswana: a population-based study of attitudes, practices, and human rights concerns," Public Library of Science Medicine 3, no. 7 (2006): e261;
46. and A. Medley et al., "Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes," Bulletin of the World Health Organization 82, no. 4 (2004): 299-307. (Pubitemid 38568468)
47. E.F. Long, M.L. Brandeau, and D.K. Owens, "The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States," Annals of Internal Medicine 153, no. 12 (2010): 778-789.
48. D. Low-Beer and R. Stoneburner, "Behaviour and communication change in reducing HIV: is Uganda unique?," African Journal of AIDS Research 2, no. 1 (2003): 9-12;
49. R. Stoneburner and D. Low-Beer, "Population-level HIV declines and behavioural risk avoidance in Uganda," Science 304, no. 5671 (2004): 714-718; (Pubitemid 38560873)
50. T.B. Hallett et al., "Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti," Sexually Transmitted Infections 82, suppl 1 (2006): 1-8;
51. S. Gregson et al., "HIV decline associated with behaviour change in eastern Zimbabwe," Science 311, no. 5761 (2006): 664-666; (Pubitemid 43191311)
52. D.T. Halperin et al., "A surprising prevention success: why did the HIV epidemic decline in Zimbabwe?," Public Library of Science Medicine 8, no. 2 (2011): e1000414.
53. F. Eboko and T. Nemeckova, "AIDS-Challenge to Health Security in Africa: Politics in Africa and Case Study on Botswana," in Facing Global Environmental Change: Environmental, Human, Energy, Food, Health and Water Security Concepts, Vol 4, Hexagon Series on Human and Environmental Security and Peace, eds H.G. Brauch et al. (New York: Springer-Verlag, 2008): 553-562.
54. Joint United Nations Programme on HIV/AIDS, 2010 Report on the Global AIDS Epidemic (Geneva, Switzerland: UNAIDS, 2010).
55. Fassin, When Bodies Remember, 189.
56. P. Piot et al., "Coming to terms with complexity: a call to action for HIV prevention," The Lancet 372, no. 9641 (2008): 845-859;
57. K. Henderson et al., "Enhancing HIV prevention: renewing the social and behavioural agenda," Global Health 4, no. 2 (2009): 117-130;
58. Anny J.T.P. Peters et al., "Where does public funding for HIV prevention go to? The case of condoms versus microbicides and vaccines," Globalization & Health 6 (2010): 23. doi:10.1186/1744-8603-6-23
59. S. Chapman, "Unravelling gossamer with boxing gloves: problems in explaining the decline in smoking," British Medical Journal 307, no. 6901 (1993): 429-432; (Pubitemid 23227473)
60. Susan Kippax, "Sexual Health Interventions Are Unsuitable for Experimental Evaluation," in Effective Sexual Health Interventions: Issues in Experimental Evaluation, eds. J.M. Stephenson, J. Imrie, and C. Bonell (Oxford: Oxford University Press, 2003): 17-34;
61. P. Hawe, A. Shiell, and T. Riley, "Complex interventions: how 'out of control' can a randomised trial be?," British Medical Journal 328, no. 7455 (2004): 1561-1563; (Pubitemid 38850320)
62. M.J. Goldenberg, "On evidence and evidence-based medicine: lessons from the philosophy of science," Social Science & Medicine 62, no. 11 (2006): 2621-2632;
63. T. Hallett, P. White, and G. Garnett, "Appropriate evaluation for HIV prevention interventions: from experiment to full scale implementation, " Sexually Transmitted Infections 83, suppl 1 (2007): i55-i60. (Pubitemid 47242474)
64. Most analyses of evaluations include only those studies-and they are usually few-that meet the following criteria: the intervention must be designed to change sexual behavior, have a behavioral and preferably a biologic outcome such as HIV/STI endpoints, and use experimental or quasiexperimental designs with comparison groups and preferably randomized allocation to intervention and control groups. See A. Oakley et al., "Sexual health education interventions for young people: a methodological review," British Medical Journal 310, no. 6973 (1995): 158-162;
65. J.B. Jemmott and J.S. Jemmott, "HIV risk reduction interventions with heterosexual adolescents," AIDS 14, suppl 2 (2000): S40- S52;
66. M. Merson, J. Layton, and K. O'Reilly, "Effectiveness of HIV prevention interventions in developing countries," AIDS 14, suppl 2 (2000): S68-S84;
67. J. Stephenson, J. Imrie, and S. Sutton, "Rigorous trials of sexual behaviour interventions in STD/HIV prevention: what can we learn from them?," AIDS 14, suppl 2 (2000): S115-S124.
68. N. Padian et al., "Weighing the gold in the gold standard: challenges in HIV prevention research," Editorial Review, AIDS 24, no. 5 (2010): 621-635. Studies included were those that (1) randomly allocated intervention and comparison groups, (2) evaluated interventions to prevent sexual transmission, and (3) reported HIV incidence as the primary or secondary outcome.
69. Niamh Stephenson, "A social public health," Editor's Choice, American Journal of Public Health 101, no. 7 (2011): 1159.
70. Robin Vincent, "Measuring social and structural change for HIV prevention" (Discussion paper presented at the UNAIDS Think Tank on Evaluation of HIV Prevention, Wilton Park, Sussex, UK, September 1-4, 2009).
71. See for instance Susan Kippax, "Understanding and integrating the structural and biomedical determinants of HIV-infection: a way forward for prevention," Current Opinion in HIV/AIDS 3, no. 4 (2008): 489-494.
72. Roy Anderson, "Prevention works" (plenary paper presented at the XIIIth International AIDS Conference, Durban, South Africa, July 9-14, 2000).
73. Global HIV Prevention Working Group, New Approaches to HIV Prevention: Accelerating Research and Ensuring Future Access (Gates Foundation/Kaiser Family Foundations, 2006);
74. Global HIV Prevention Working Group Bringing HIV Prevention to Scale: An Urgent Global Priority (Gates Foundation/Kaiser Family Foundations, 2007);
75. Global HIV Prevention Working Group, Behavior Change and HIV Prevention: Re(Considerations) for the 21st Century (Gates Foundation/Kaiser Family Foundations, 2008).
76. For example: HIV incidence rates in northern Europe and North America have declined especially among that population most at risk-gay men. See P. Sullivan et al., "Re-emergence of the HIV epidemic among men who have sex with men in North America, Europe and Australia 1996-2005," Annals of Epidemiology 19, no. 6 (2009): 423-431.
77. See R. Stall et al., "Running in place: implications for HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries," AIDS & Behavior 13, no. 4 (2009): 615-629.
78. See N. Punyacharoensin and C. Viwatwongkasem, "Trends in three decades of HIV/AIDS epidemic in Thailand by nonparametric back calculation method," AIDS 23, no. 9 (2009): 1143-1152;
79. they used a nonparametric back calculation method and demonstrated that HIV incidence in Thailand had declined in 3 decades and was at its highest in the 1990s. Since 2002, the HIV incidence rate in Thailand has been less than 0.1%. In Brazil, the prevalence of HIV among adults halved between the beginning of the 1990s and 1995 and since 2000 has been stable at 0.6% among Brazilians aged between 15 and 49 years. See S. Oakie, "Fighting HIV-lessons from Brazil," New England Journal of Medicine 354, no. 19 (2006): 1977-1981.
80. And Garnett and colleagues have shown that HIV-prevention efforts have been successful in Africa-at least in a limited fashion-in Uganda, Zimbabwe, Kenya, Rwanda, Ethiopia, and Malawi. See G. Garnett et al., "Measuring and interpreting national trends" (paper presented at UNAIDS Think Tank on Evaluation of HIV Prevention, Wilton Park, Sussex, UK, September 1-4, 2009).
81. Social change, because it is particular and local, needs to be assessed by descriptive methods, by monitoring of HIV incidence and prevalence, and risk practices, description of prevention programmes, and by modeling, where the assumptions of the model are based on surveillance and sociobehavioural data. Although randomized controlled trials may be the best way to evaluate the efficacy of a particular intervention, as D.P. Wilson and G.P. Garnett noted in "Introduction to recent developments in HIV epidemic modeling," Current Opinion in HIV and AIDS 6, no. 2 (2011): 91-93
82. "[C]linical trials are not designed to measure the long-term impact of the intervention or the population-level impact" (p.91).
83. The Joint United Nations Programme on HIV/AIDS (UNAIDS), The International Group on Analysis of Trends in HIV Prevalence Behaviours in Young People in Countries most Affected by HIV, "Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV," Sexually Transmitted Infections 86, suppl 2 (2010): ii72-ii83.
84. For example, despite a reduction in HIV incidence of around 30% between 2000 and 2008, South African HIV incidence rates remain disturbingly high. See L. Johnson et al., "The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis," advance online access Journal of the Royal Society Interface, December 23, 2012;
85. Q. Abdool Karim et al., "Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa," International Journal of Epidemiology, advance online access November 3, 2010. And in some high-income countries where there was a decline in HIV incidence among gay men between 1996 and 2000, these declines have been followed by increases in HIV notification rates between 2000 and 2005.
86. See Sullivan et al., "Re-emergence of the HIV epidemic," 423-431;
87. Stall et al., "Running in place," 615-629.
88. Catherine M. Campbell, Letting Them Die: Why HIV/AIDS Prevention Programmes Fail, (Oxford: Indiana University Press, 2003).
89. S. Kippax and K. Race, "Sustaining safe practice: twenty years on," Social Science & Medicine 57, no. 1 (2003): 1-12; (Pubitemid 36566515)
90. W. Bowtell, Australia's Response to HIV/AIDS 1982-2005. Report prepared for Research and Dialogue Project on Regional Responses to the spread of HIV/AIDS in East Asia organised by the Japan Center for International Exchange and the Friends of the Global fund to Fight AIDS, Tuberculosis and Malaria (Sydney: Lowy Institute for International Policy, 2005);
91. A. Mindel and S. Kippax, "A national strategic approach to improving the health of gay and bisexual men: experience in Australia," in The New Public Health and STD/HIV Prevention: Personal, Public and Health System Approaches, eds S.O. Aral and K. Fenton (Atlanta, GA: Centers for Disease Control and Prevention, in press).
92. D. Low-Beer and R. Stoneburner, "Uganda and the challenges of HIV/AIDS," in The Political Economy of AIDS in Africa, eds N. Poku and A. Whiteside (Aldershot, England: Ashgate, 2004): 165-190;
93. Stoneburner and Low-Beer, "Population-level HIV declines," 714-718;
94. Robert Thornton, Unimagined Community: Sex, Networks, and AIDS in Uganda and South Africa (Berkeley: University of California Press, 2008).
95. Halperin et al, "A surprising prevention success," e1000414.
96. See Stall et al., "Running in place," 615-629;
97. they compared the surveillance data between 1996 and 2000 from North America, Western Europe (France, Germany, the Netherlands, United Kingdom), and Australia. See Sullivan et al., "Re-emergence of the HIV epidemic," 423-431;
98. Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report (Sydney: National Centre in HIV Epidemiology & Clinical Research, The University of New South Wales, 2009).
99. D. Bernard, S. Kippax, and D. Baxter, "Effective partnership and adequate investment underpin a successful response: key factors in dealing with HIV increases," Sexual Health 5, no. 2 (2008): 193-201. (Pubitemid 351786446)
100. Ugandan AIDS Commission, Uganda UNGASS Progress Report, Jan 2008-Dec 2009. (Uganda, Ugandan AIDS Commission, 2010).
101. Halperin et al., "A surprising prevention success," e1000414.
102. Bowtell, Australia's Response to HIV/AIDS 1982-2005.
103. Low-Beer and Stoneburner, "Uganda and the challenges of HIV/AIDS," 165-190.
104. Halperin et al, "A surprising prevention success," e1000414.
105. Thornton, Unimagined Community.
106. Bowtell, Australia's Response to HIV/AIDS 1982-2005.
107. Mindel and Kippax, "A national strategic approach to improving the health of gay and bisexual men."
108. Halperin et al, "A surprising prevention success," e1000414; and Thornton, Unimagined Community.
109. J. Auerbach et al., "Addressing social drivers of HIV/AIDS: some conceptual, methodological and evidentiary considerations," aids2031, working paper no. 24, Social Drivers Working Group (2009);
110. G.R. Rao Gupta et al., "Structural approaches to HIV prevention," The Lancet 372, no. 9640 (2008): 764-775.
111. There are 10 million people who need antiretroviral treatment today and only around 5 million are receiving it. Furthermore, maintaining millions of people on treatments throughout their lifetime is not sustainable (Michel Sidibe, an interview with Michel Sidibe by Regina McEnery, IAVI Report: The Publication on AIDS Vaccine Research 14 [2010]: 12-13).
112. D.N. Burns, C.W. Dieffenbach, and S.H. Vermund, "Rethinking prevention of HIV type 1 infection," Clinical Infectious Disease 51, no. 6 (2010): 725-731.
113. J. Steinberg, AIDS and AIDS Treatment in a Rural South African Setting. Monograph 149, (Pretoria, South Africa: Institute for Security Studies, 2008).
114. C. Courtenay-Quirk et al., Urban Men's Study Team, "Is HIV/AIDS stigma dividing the gay community? Perceptions of HIV-positive men who have sex with men," AIDS Education and Prevention 18, no. 1 (2006): 56-67.
115. Fee and Krieger, "Understanding AIDS," 1477-1486.
116. Marsha Rosengarten, HIV Interventions: Biomedicine and the Traffic Between Information and Flesh (Seattle, WA: University of Washington Press, 2009).